England’s National Institute for Health and Care Excellence has rejected Keytruda (pembrolizumab) in patients who receive locally advanced or metastatic urothelial carcinoma who have had platinum-containing chemotherapy.
Merck sponsors Keytruda.
The drug has since been removed from the Cancer Drug Fund, where it was available previously.
The National Institute for Health and Care Excellence said it couldn’t recommend the drug because of cost-effectiveness.
